Business

Novartis appoints Elizabeth Barrett as Oncology Head

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018. She will be based in Basel. Mrs. Barrett succeeds Bruno Strigini who decided to retire from Novartis for personal reasons.

Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. Both of these breakthrough therapies have the potential to benefit a number of different patient populations and this strategic investment will enable the companies to evaluate cemiplimab and dupilumab in broad clinical development programs.

European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted a marketing authorisation for Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). The approval is based on results from the phase III ALEX study,

Groundbreaking gene therapy trial set to cure hemophilia

A 'cure' for haemophilia is one step closer, following results published in the New England Journal of Medcine of a groundbreaking gene therapy trial led by the NHS in London. Clinical researchers at Barts Health NHS Trust and Queen Mary University of London have found that over one year on from a single treatment with a gene therapy drug, participants with haemophilia A (the most common type) are showing normal levels of the previously missing protein, and effectively curing them.

Boehringer Ingelheim marks great progress in immuno-oncology research partnerships in 2017

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim's two-pronged research strategy - investigating both cancer cell-directed therapies and immune cell-directed therapies.

Dr. Rentschler Holding and Rentschler Biopharma choose prevero's BI solution

prevero, a unit4 company and software provider for Business Intelligence and Corporate Performance Management solutions, has been selected by the global biopharmaceutical manufacturer Rentschler Biopharma, and its parent Dr. Rentschler Holding, to improve business insights across the company's subsidiaries. The company was looking for a Business Intelligence (BI) tool to facilitate faster business decisions, detailed planning, and more meaningful reporting while enabling the simulation of different business scenarios.

Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children

Novartis announced that the European Commission (EC) approved Tasigna® (nilotinib) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) and pediatric patients with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.

Business

More Pharma News ...